Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKIPP2 cabozantinib dose skipping study in advanced renal cell carcinoma
NL-OMON58823Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib in renal cell carcinoma (RCC), sponsored by Leiden University Medical Center. Primary endpoints: AUC0-72 comparability and Ctrough comparability. Started Jan 2026; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON58823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58823.